Subscribe to our Email Alerts
Menu
Home
About Us
Company Overview
Company Values
Board of Directors
Executive Management
Corporate Directory
Products
DAYBUE™ (trofinetide)
Pipeline
Pipeline
Trofinetide
Rett Syndrome
NNZ-2591
Phelan-McDermid Syndrome
Angelman Syndrome
Pitt Hopkins Syndrome
Prader-Willi Syndrome
Hypoxic-ischemic encephalopathy
Science
Science Behind Neuren's Products
Trofinetide Published Studies & Presentations
Rett Syndrome
NNZ-2591Published Studies & Presentations
Phelan-McDermid Syndrome
Pitt Hopkins Syndrome
Angelman Syndrome
Investors
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
News & Media
Media
Contact
Contact Us
Email Alerts
Investors
Home
>
Investors
>
ASX Announcements
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
ASX Announcements
Filter by Year:
2025
2024
2023
2022
2021
2020
2019
2018
Older
May 27, 2024
Pitt Hopkins syndrome Phase 2 trial results presentation
May 27, 2024
Phase 2 trial shows significant improvements in Pitt Hopkins
May 23, 2024
Trading Halt
May 16, 2024
Neuren CEO to present at BIO & Jefferies conferences in US
May 15, 2024
Investor presentation, 15 May 2024
May 09, 2024
DAYBUE Q1 net sales US$75.9m, full-year guidance US$370-420m
May 07, 2024
Notification of cessation of securities - NEU
Apr 26, 2024
Notification of cessation of securities - NEU
Apr 26, 2024
Virtual AGM online guide
Apr 26, 2024
Notice of Annual General Meeting/Proxy Form
Previous
1
2
3
4
5
6
7
Next
